Advertisement

Topics

STAT Plus: Pharmalittle: FDA votes ‘no’ on J&J drug, Teva in turmoil, and stock slumps

09:17 EDT 3 Aug 2017 | STAT

An FDA advisory panel voted 12 to 1 that the benefits of an experimental Johnson & Johnson medicine for rheumatoid arthritis do not outweigh the risks.

Original Article: STAT Plus: Pharmalittle: FDA votes ‘no’ on J&J drug, Teva in turmoil, and stock slumps

NEXT ARTICLE

More From BioPortfolio on "STAT Plus: Pharmalittle: FDA votes ‘no’ on J&J drug, Teva in turmoil, and stock slumps"

Quick Search
Advertisement
 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...